3.18 USD
↘ 0.10 (3.05%)AT CLOSE (11:59 AM EDT)
Editas Medicine, Inc. Common Stock
EDITNASDAQ • USD
3.21
↗ 0.03 (0.94%)
POST MARKET (AS OF 07:50 PM EDT)
Post Market
AS OF 07:50 PM EDT
3.21
↗ 0.03 (0.94%)
Market: CLOSED
Editas Medicine, Inc. Common Stock (EDIT) trades at $3.17 per share. The technical outlook is "Strong Buy" and the fundamental picture shows "Neutral". This is driven by a concerning Altman Z-Score in the distress zone, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. On the valuation front, EDIT trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.
Technical & fundamental data as of Aug 26, 2026.
Open?$3.40
High?$3.52
Low?$3.16
Prev. Close?$3.28
Volume?2.9M
Avg. Volume?2.0M
VWAP?$3.25
Rel. Volume?1.45x
Bid / Ask
Bid?$3.16 × 300
Ask?$3.19 × 300
Spread?$0.03
Midpoint?$3.18
Valuation & Ratios
Market Cap?503.7M
Shares Out?153.6M
Float?148.8M
Float %?96.9%
P/E Ratio?N/A
P/B Ratio?4.78
EPS?-$0.48
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
Employees
87
Market Cap
503.7M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2016-02-03
Address
11 HURLEY ST.
CAMBRIDGE, MA 02141
Phone: 617-401-9000
CAMBRIDGE, MA 02141
Phone: 617-401-9000
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?40
Z-Score?0
Momentum?85
Short Sent.?14
Piotroski F-Score?4/9Mixed
Altman Z-Score?-7.67Distress
Confidence?51%Low
Short InterestVery High
Short % of Float?16.59%High
Short Interest?24.7M
Days to Cover?14.6
Free Float148.8M
Avg Daily Volume1.7M
Settlement Date2026-08-14
Financial Health
Current Ratio?3.19Strong
Quick Ratio?3.19Strong
Cash Ratio?2.66Strong
Debt/Equity?0.53Moderate
ValuationFAIRLY VALUEDvs 3 peers + S&P 500
Score58/100
P/E?N/A▾
P/B?4.78FAIR▾
Peers25
S&P38
P/S?10.72HIGH▾
Peers100
S&P7
P/FCF?N/A▾
EV/EBITDA?-4.7CHEAP▾
S&P97
EV/Sales?8.03HIGH▾
Peers100
S&P17
Returns & Efficiency
ROE?-70.2%WEAK▾
S&P3
ROA?-31.2%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-120550000
Enterprise Value?$377.7M
Fundamentals ratios updated end of day